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That  part  of B  cell  differentiation  which  begins in  the  reaction  of antigen  with 
surface  immunoglobulin  (sIg) 1 receptors  and  ends  in  the  production  of antibody- 
secreting cells comprises a complex train of discrete events (1, 2). An important aspect 
of this process concerns the chemical signals, positive and negative, and their corre- 
sponding receptors, whereby the steps in this process are regulated. In this report, we 
present  further  evidence  for  the  participation  of Lyb-2,  a  cell  surface  component 
expressed only in the B cell lineage, in the mechanism of B cell activation. 
We have already shown that monoclonal Lyb-2 alloantibody (me-a-Lyb-2) inhibits 
the generation of antibody-forming cells (AFC) to sheep erythrocytes (SRBC) but not 
to  the  T-independent  antigens  trinitrophenylated  (TNP)-Ficoll  and  TNP-Brucella 
abortus.  This  inhibition  cannot  be  ascribed  to  a  change  in  the  kinetics  of  AFC 
generation  nor to any known  variety of suppression  (3).  Because mc-c~-Lyb-2.1 did 
not inhibit  generation of AFC from Lyb-2.1/Lyb-2.2 heterozygous cells, we inferred 
that Lyb-2 antibody causes inhibition by blocking rather than by providing a negative 
or suppressive signal (3). 
To define the function of Lyb-2 more closely, we have now tested the ability of mc- 
c~-Lyb-2.1  to  block  the  ability  of B  cells  to  receive  signals  that  are  known  to  be 
required  for differentiation of B  cells to AFC.  These data signify that  Lyb-2 is  not 
concerned in the reception of soluble factors contained in mixed lymphocyte culture 
(MLC)  or macrophage (M~)  culture supernatants  (SN), but  is involved in an early 
phase  of activation  before B  cells  become overtly receptive  to  such  differentiative 
signals. 
Materials and Methods 
Mice.  Except for C57BL/6 mice (purchased from The Jackson Laboratory, Bar Harbor, 
ME), all were obtained from colonies at Memorial Sloan-Kettering Cancer Center. 
Antigens.  SRBC  and  horse  erythrocytes (HRBC)  were purchased  from Gibco Diagnostics 
Laboratories, Madison, WI, and Colorado Serum Co., Denver, CO, respectively. 
Antibody.  Monoclonal a-Lyb-2.1 antibody (clone 9-6.1) is described  elsewhere  (3). 
* Supported in part by grants CA-22131 and AI-00329 from the National Institutes of Health~ 
:~ American Cancer Society research professor  of cell surface immunogenetics. 
' Abbreviations used in this paper: a, anti; AFC, antibody-forming  cells; C, complement; FBS, fetal bovine 
serum; HRBC, horse erythrocytes; IL-1, IL-2, interleukin I, 2; LPS, lipopolysaccharide; mc, monoclonal; 
MDM, Mishell-Dutton medium; M~;  macrophages; MLC, mixed lymphocyte culture;  PFC, plaque- 
forming cells; sIg, surface immunoglobulin; SN, supernatant; SRBC, sheep erythrocytes; TCGF, T cell 
growth factor; TNP, trinitrophenylated. 
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Cell Preparations 
T-DEPLETED SPLEEN CELLS.  T cells were eliminated by exposure of spleen cells (3 X 107/ml) 
to mc-ot-Thy-l.2 (1:100)  and then, after washing, to selected  rabbit serum  (complement [C] 
1:9). The cycle was then repeated with mc-a-Lyt-1.2 (1:25) plus mc-a-Lyt-2.2 (1:25) in place of 
a-Thy-l.2. The two  treatments were needed because spleen cells subjected to only the first 
treatment  did  generate  substantial numbers of a-SRBC  PFC  when  exposed  to  mitogenic 
quantities of concanavalin A (4/~g/ml), whereas twice-treated cells did not. The fact  that the 
two treatments reduced a-SRBC PFC generation by 95%  in the presence of purified T  cell 
growth factor (TCGF; kindly provided by Dr. Steven Gillis, Fred Hutchinson Cancer Research 
Center, Seattle,  WA)  further emphasizes the efficacy  of the dual procedure  in eliminating 
residual T cells. 
B CELLS.  To remove Mq~, spleen cells  (~18  ×  107) were  passed over a  Sephadex G-10 
column (bed volume, 30 ml; Pharmacia Fine Chemicals, Div. of Pharmacia Inc., Piscataway, 
N  J) and eluted with ~30 ml of RPMI 1640 (Grand Island Biological Co. Grand Island, NY) 
containing 20% fetal bovine serum (FBS) streptomycin (100 #g/ml) and penicillin (100 U/ml) 
(4).  Recovery was  consistently 50-60%  of the  starting population. This  treatment  did  not 
change the proportion of T and B cells significantly,  but reduced the esterase-positive cells from 
5-9% to <0.5% (5). Efficacy  of this procedure was further confirmed by functional assays (see 
Results). The eluted cells were treated with mc-a-Thy-1.2 plus mc-c~-Lyt-1.2 and me-a-Lyt-2.2, 
and C, to eliminate T cells (see above). 
Mq~.  Spleen cells (5 ×  107) in 15 ml of RPMI 1640 plus 20% FBS were plated in each 100- 
ram plastic culture dish and incubated at 37°C in a humidified atmosphere of 10% CO2 and 
90% air for 2 h. Nonadherent cells were then washed away, and adherent cells detached with 
a rubber policeman. The adherent cells were treated with mc-a-Thy-l.2 plus C and irradiated 
(1,500 rad). In the following text, these adherent Thy-1- and radi,  oresistant cells are referred to 
as Mq~. 
Mishetl-Dutton Culture.  Spleen cells,  T  depleted or  purified  (as  above), were  cultured in 
RPMI 1640 supplemented with 10% FBS, L-glutamine (2 raM), 2-mercaptoethanol (5 ×  10  -s 
M), sodium pyruvate (1  raM), streptomycin (100 #g/ml), penicillin (100 U/ml), and Hepes 
buffer (10 mM) in 16-ram flat-bottomed Linbro plates (Linbro Chemical Co., Hamden, CT) 
with SRBC (5 ×  106) at 37°C in a humidified atmosphere of 10% CO2 and 90% air with daily 
feeding as described elsewhere  (3). 
Plaque-forming Cell (PFC) Assay.  Direct a-SRBC or a-HRBC PFC counts were determined 
on day 5 by the slide version (6) of the Jerne plaque assay. Results are expressed  as mean PFC 
counts per culture +  SEM or a  percentage of the standard control PFC response (100 [PFC 
experiment]/[PFC control]). 
Preparation of Factors 
MLC-SN.  5 ×  106 B6 spleen cells were stimulated with 5 ×  106 irradiated DBA/2 spleen 
cells (2,000 rad) in 1 ml of Mishell-Dutton medium (MDM) in a Linbro well. 24 h later, the 
supernatant was centrifuged, passed through 0.45-#m filter (Millipore Corp., Bedford, MA), 
and stored at -20°C. This preparation showed a low but significant level of interleukin 2 (IL- 
2) activity determined by TCGF assay, and may contain a factor similar to late-acting T cell- 
replacing factor.  The B cell helper activity of Mq~-derived factors  (e.g., IL-1) was minimized by 
reducing the concentration of MLC-SN (see Results). 
SUPERNATANT FROM P388D.| CELLS  (MI~-SN),  As  a  source of M~b-derived factors,  2  ×  106 
P388D. 1 cells  (a DBA/2 M~ cell line kindly provided by Dr. Peter Ralph, Memorial Sloan- 
Kettering Cancer Center)  were  cultured in  1 ml of MDM  with 0.01 /xg/ml Escherichia coli 
lipopolysaccharide (LPS; 055:B5, Difco Laboratories, Detroit, MI) in a Linbro well for 4 d (7). 
The cell-free SN was dialyzed against 100 vol of RPMI 1640 for 24 h, filtrated, stored at -20°C, 
and used at a concentration of 0.5%. 
Results 
Properties of the MLC-SN and M~b-SN Preparations Used, and Relative Homogeneity of the 
Selected Cell Population Tested (Data  in  Table I).  Without  MLC-SN,  no  PFC  were YAKURA,  SHEN,  BOURCET,  AND  BOYSE  1311 
TASL~  I 
Properties of the MLC-SN and Mdp-SN Preparations Used, and Relative Homogeneity of the Selected Cell 
Populations Tested* 
Soluble factors  Spleen cells 
B(T 
B+M~  andM$  M4, 
Concentration of MLC-  M$-SN  (T de-  de- 
SN (added on day 2)  (0.5%)  pleted:  pleted:  (× 10-4)* 
5x  I0  ~)  5x  106  ) 
a-SRBC PFC per culture 
% 
First experiment 
30  +  -  -  8605 +  429 
-  +  --  3924 ±  331  (54 %§) 
20  +  --  -  4185 zt: 94 
-  +  -  798 ±  27  (81%§) 
--  +  2  1401  ±  85 
-  +  4  3822 +  370 
--  +  8  4141 :k 254 
-  -  8  0±0 
10  +  --  -  1800 :t: 102 
-  +  -  96+13  (95%§) 
none  +  -  -  0 ::t: 0 
-  +  -  0±0 




-  -  +  -  479 +  19 
+  (day 0)  -  +  -  5806 +  735 
+  (day 1)  -  +  -  4070 :t: 461 
+  (day 0)  -  +  -  330 zlz 20 
+  (day 1)  -  +  -  160 +  10 
-  -  +  -  0:t:0 
* Two of several similar experiments are shown. 
:1: See Materials and Methods. 
§Percent reduction caused by removal of M4~ =  100 (1 -  a/b), where a =  response for B cells alone, and b 
=  response for B +  M4~. 
generated  by  T-depleted  spleen  cells  alone  (B  +  Mdp),  nor  by  B  cells  or  M4,  alone. 
Removal  of M~  (from  the T-depleted  spleen population)  reduced  the PFC  response 
by  95%  in  the presence  of  10%  MLC-SN,  by  81%  with  20%  MLC-SN,  and  by  54% 
with  30%  MLC-SN.  This  reduction  in  PFC  by removal  of M4~ was  proportionately 
abrogated  by  replacing  M~  in  increasing  numbers  (experiment  1),  or  by  providing 
Mq~-SN  (from the P388D. 1 cell line), which alone cannot  help B  cells but  restores the 
B  cell response in the presence of 15% MLC-SN  (experiment  2). 
Thus,  the  MS  depletion  procedure  is  evidently  adequate.  At  high  concentration, 
the MLC-SN  preparation  used has appreciable  MS-replacing  activity (possibly of M~ 
origin,  e.g.,  IL-1),  but  this activity  is  negligible at  the selected  concentration  of  10- 
15% MLC-SN.  Therefore, under  the conditions described, the helper actions of MLC- 
SN and Mq~-SN can be ascribed to T  cells and Mq~, respectively, and both are required 
for maximal  PFC  response. 
Evidence  That  Lyb-2  Antibody  Acts  on  B  Cells  and Not  on  Mep  (Table  II).  MS  were 1312  Lyb-2 IN EARLY  B CELL ACTIVATION 
TABLE II 
Lyb-2 Antibody Acts on B Cells, Not on M(O 
Composition of culture 
B cells  MO 
(5 x  106)  •  (x to-')~ 
o~-SRBC per culture  Percent 
With mc-a-Lyb-  Without mc-ot-  response 
2.1 (A)  Lyb-2.1 (B)  (IOOA/B) 
B6-Lyb-2.1  B6-Lyb-2.1  (8) 
B6-Lyb-2.1  B6-Lyb-2.1  (4) 
B6  B6  (8) 
B6  B6  (4) 
B6-Lyb-2.1  B6  (8) 
B6-Lyb-2.1  B6  (4) 
B6  B6-Lyb-2.1 (8) 
B6  B6-Lyb-2.1 (4) 
226 ± 23  2288 ±  169  10 
432 ± 58  1636 ± 86  26 
2693 ±  113  3126 ± 276  86 
1283 ± 73  1649 ±  117  78 
745 ± 95  3864 ±  177  19 
452 ±  70  1556 ± 88  29 
2999 ±  110  2780 ± 216  108 
1516 ± 67  1397 ±  129  109 
Combinations of B cells and Mq~, as indicated, were cultured with SRBC in the presence or absence of 2% 
mc-a-Lyb-2.1. On day 2, 15% MLC-SN was added to each culture, and a-SRBC PFC were assayed on day 
5. 
* PFC responses of B cells with neither Mq~ nor MLC-SN were nil for B6-Lyb-2.1 and B6 cells. Responses 
of B cells with MLC-SN but without Me were 183 +  15 for B6-Lyb-2.1 cells and 250 + 30 for B6 cells. 
PFC responses of Mq~ with and without MLC-SN were nil. 
defined for the present purposes as the adherent, T  cell-depleted, radioresistant spleen 
cell population  (see Materials and  Methods).  The aim of the following experiments 
was  to  gain  further  evidence  that  accessory cells meeting these  criteria are not  the 
target of mc-a-Lyb-2 antibody. For this purpose, B cells (see Materials and Methods) 
and Mq, were each prepared from B6 (Lyb-2.2) and B6-Lyb-2.1 congenic mice. These 
cells were  then  combined in  all four possible combinations of B  cells with  M~ and 
cultured with or without mc-a-Lyb-2.1 antibody. On day 2,  15% MLC-SN was added 
as a  source of T  helper factors, and PFC were assayed on day 5. Table II shows that 
PFC counts were reduced by mc-a-Lyb-2.1  antibody only when  the purified B  cells 
were of phenotype Lyb-2.1; the Lyb-2 genotype of the Mq~ was immaterial. Evidently, 
B  ceils are the only target of Lyb-2 antibody. 
Lyb-2 Antibody Does Not Block Reception  of Helper Factors  Present  in MLC-SN or MO-SN 
(Table III).  The fact that Lyb-2 antibody blocked generation of PFC to T-dependent 
but not to T-independent antigen (3) could mean that Lyb-2 antibody interferes with 
a  reaction between T  and  B  cells, one such reaction being the reception of T  helper 
factors  by  B  cells.  Accordingly, having  shown  that  the  background  helper  activity 
attributable  to  Mq~  factors  in  15%  MLC-SN  is  negligible  (Table  I),  we  tested  the 
possibility that  Lyb-2  molecules  serve  as  receptors  for  T  helper  factors.  For  this 
purpose, we used T-depleted spleen cell (B +  M~)  as responder cells, and  MLC-SN 
(15%), added at 44 h, as a  source of T  helper factors. Representative data are given 
in  Table  III  (experiment  1).  The  rationale for these experiments  was  that  if Lyb-2 
antibody acted simply by blocking the receptor sites for T  helper factors, then Lyb-2 
antibody added at  44  h,  the time of adding MLC-SN,  should  effectively block the 
response.  In the event, when  antibody was  added at  the initiation of culture,  there 
was  maximal  PFC  reduction,  but  when  antibody was  added at  44  h  there  was  no 
reduction.  These  results  indicate  that  Lyb-2  is  not  involved  in  the  reception  of T 
helper factors present in MLC-SN, and imply that  Lyb-2 functions at some point in 
a  process  that  occupies  about  44  h  after  stimulation  by  antigen  and  precedes  the 
operation oft  helper factors. This places the time of action of Lyb-2 antibody within YAKURA,  SHEN,  BOURCET,  AND  BOYSE  1313 
TABLE  III 




Responding cells  MLC-SN  response on day 5 
(15%) at  B6 
(5 ×  106)  mc-a-Lyb-2.1  M@SN  44 h  B6-Lyb-  (con- 
(l: 100)  (0.5%)  2.1  trol) 
Time of addition of: 
1"  B +  Mq~ (T depleted) 
% standara°'4 
--  +  100  100 
--  -  0  0 
0 h  +  13  92 
20 h  +  50  93 
44 h  +  113  101 
2§  B cells  0 h  +  100  100 
--  +  8  8 
Oh  -  3  4 
--  -  0  0 
0 h  0 h  +  24  90 
20 h  0 h  +  40  107 
44 h  0 h  +  91  121 
3§  B cells  --  44  h  +  100  100 
--  44  h  -  7  2 
0 h  44 h  +  17  95 
20 h  44 h  +  55  98 
44 h  44 h  +  89  110 
* One of four similar experiments. 
~: Standard responses (without antibody) per culture: B6-Lyb-2.1, 5545  -. 874 (experiment 1), 3190 +  442 
(experiment  2),  and  2634  ±  298  (experiment  3);  and  B6,  3980  ±  291  (experiment  1),  4070  :k  461 
(experiment 2), and 2257  +  80 (experiment 3). 
§ One of two similar experiments. 
TABLE  IV 
Period of Action of Lyb-2 Antibody 
Period of culture with mc-a-Lyb-2.1  PFC response 
(1:100)  plus SRBC 
% standard 
2 h  79 
4 h  72 
20 h  23 
Purified B cells (5 ×  106) from B6-Lyb-2.1 mice were cultured with SRBC plus 
mc-a-Lyb-2.1 for the period of time indicated, after which SRBC were lysed 
and the cells washed four times. 5 ×  106 of these cells were then cultured with 
SRBC, with addition of 0.5% Mdp-SN at 20 h and 10% MLC-SN at 44 h. 
* 5  d  after  exposure  to  SRBC:  100  (PFC  with  antibody)/(PFC  without 
antibody). 
the  phase  of  B  cell:M~  interaction,  and  focuses  attention  on  the  reception  of M~ 
signals by B  cells or on the actual  triggering  of B  cells by antigen. 
Experiments  2  and  3  of Table  III  were  directed  to  the  former  possibility,  namely 
that  reception  of Mq~ signals is impeded  by Lyb-2  antibody.  Purified  B  cells were used 1314  Lyb-2 IN EARLY B CELL ACTIVATION 
TABLE V 
Lyb-2 Antibody Affects Only Antigen-triggered B Cells 
Ist culture  2nd culture  Group  (20 h) with  with:  a-Lyb-2 plus: 
PFC response 
a-SRBC  a-HRBC 
% standard* 
A  SRBC  SRBC  27 _+ 3  NT~ 
B  --  SRBC  76 + 7  NT 
C  SRBC  HRBC  NT  83 ±  13 
Procedures as in Table IV. 
* On day 5 after first exposure to SRBC (groups A and B) or to HRBC (group 
C); means of two experiments. 
Not tested. 
as responder cells,  P388D. 1 supernatant as a  source of Mth-derived factors (M~SN), 
and MLC-SN as a  source of T  helper factors. The rationale was again that if Lyb-2 
antibody blocks reaction of Mth-derived  factors with  B  cells,  then  antibody should 
inhibit the PFC response when added together with MO-SN at 0 or 44 h. This is not 
the case: when M~-SN and antibody were added together at the initiation of culture, 
there was maximal PFC reduction  (experiment  2),  but  when Mth-SN and antibody 
were added  together at  44 h,  there was very little  reduction  (experiment  3).  These 
data imply that  reception of M~derived  factors represented  in  P388D. 1 Mth-SN is 
not blocked by Lyb-2 antibody. 
Evidence That Lyb-2 Antibody Acts During the Triggering of B  Cells by Antigen 
PERIOD  OF  ACTION  OF LYB-2  ANTIBODY.  Purified B cells were exposed to SRBC plus 
Lyb-2 antibody for 2-20 h, freed of SRBC, washed, and cultured with fresh SRBC. 
M@SN (0.5%) and MLC-SN (10%) were added at  20 and 44 h, respectively. Table 
IV indicates that maximal reduction of PFC by Lyb-2 antibody requires the presence 
of this antibody for >4 and <20 h after exposure to antigen. 
ONLY  ANTIGEN-TRIGGERED B  CELLS ARE AFFECTED BY  LYB-2 ANTIBODY.  In the exper- 
iments summarized in Table V, purified B cells  were cultured with Lyb-2 antibody 
for 20 h, with or without SRBC, and the SRBC and excess  antibody then removed. 
The cells  were then cultured again, without antibody, with either SRBC or HRBC. 
Mt~-SN and MLC-SN were added at 20 and 44 h, respectively, after the first exposure 
to SRBC or HRBC (whichever was to assayed for PFC response). Group A of Table 
V  shows again  (as  in  Table  IV)  that  exposure to  SRBC  plus  Lyb-2 antibody  (1st 
culture) abolished the subsequent capacity of the responding population (2nd culture) 
to give a  maximal PFC response to SRBC in the absence of Lyb-2 antibody. Group 
B  shows that  exposure  to  Lyb-2 antibody alone  in  the  absence of antigen  did  not 
affect the subsequent response to SRBC. Group C  shows that the exposure to SRBC 
plus  Lyb-2 antibody did  not  affect the subsequent  PFC  response to  HRBC. Thus, 
Lyb-2 antibody evidently acts during the triggering process induced by reaction of 
antigen with B cells. Blocking by Lyb-2 antibody activity cannot be explained simply 
as a negative effect on all B cells regardless of their specificities. 
Discussion 
Of the several possible mechanisms whereby Lyb-2 antibody might block T-assisted 
generation of PFC,  some can  now be  excluded.  Lyb-2 antibody does  not  interfere YAKURA, SHEN, BOURCET, AND  BOYSE  1315 
with reception of M~-derived factors in the supernatant of P388D. 1 cells, nor with 
the  reception of MLC-associated  factors, and  its  time of action  is  previous to  the 
acquisition of responsiveness to these signals. This places the function of Lyb-2 within 
the  period  of antigen-triggered  B  cell  stimulation.  The  fact  that  Lyb-2  antibody 
blocks  the  generation  only of PFC  derived  from  B  cells  concurrently exposed  to 
antigen (the remaining B cells responding normally to a subsequent second antigen 
after Lyb-2 antibody is removed) indicates that the Lyb-2 cell surface component is 
somehow involved in a differentiative process ('proliferative' step) initiated by binding 
of antigen.  The Lyb-2 molecule is  not  the sIg receptor for antigen:  its structure is 
inappropriate (8), rabbit a-mouse Ig does not block serological absorption of a-Lyb- 
2  (unpublished  data),  and  there is  no known  reason why blocking of the  antigen 
receptor should affect only T-dependent antigen. 
Two sorts of action, not necessarily exclusive of one another, can be suggested for 
the  function of Lyb-2. First,  Lyb-2 may be involved in  internal  transmission of a 
proliferative stimulus,  for example, the mitogenic component in FBS, which in our 
experience (unpublished results) is needed for an a-SRBC response but is not essential 
to demonstrable TNP-Ficoll and TNP-Brucella responses. In the same context, Lyb-2 
may participate in molecular rearrangements ('cross-linking') ofsIg receptors required 
for response to T-dependent antigen. 
Second,  Lyb-2  molecules  might  be  concerned  in  the  phenotypic  expression  or 
presentation of receptors for differentiative signals from Mq~ or T  cells, presumably 
affecting their numbers, affinity, or conformation. The finding that MLC-SN is more 
effective on day 2 of culture than  at  the start  (9)  may be a  hint  that  the receptor 
phenotype, as well as the number of responsive B cells, is important to efficient PFC 
generation. In this context, the report that resting or unstimulated B cells were not 
responsive to proliferative and  differentiative signals  until  stimulated  by LPS  (10) 
makes us wonder whether the expression and display of signal receptors on B cells are 
subject to the same kinds of regulation as hormone receptors in classical endocrine 
system (11,  12). 
Summary 
The generation of plaque-forming cells (PFC) to T-dependent antigen, but not to 
T-independent antigen,  is reduced in  vitro by Lyb-2 antibody.  Monoclonal Lyb-2 
antibody, added to Mishell-Dutton cultures within the first 2 d, but not later, greatly 
reduces the generation of a-sheep erythrocyte (SRBC)  PFC from T-depleted spleen 
cells  whether  help  is  provided  in  the  form  of intact  T  cells  or  as  soluble  factors 
contained in mixed lymphocyte culture (MLC) supernatants. Generation of a-SRBC 
PFC  from  purified  B  cells,  assisted  by  soluble  factors  in  MLC  and  macrophage 
(P388D.1 cell) supernatants, is similarly reduced by Lyb-2 antibody. The initial 2-d 
period, during which cultures are diminishingly sensitive to reduction of PFC gener- 
ation by Lyb-2 antibody, is not affected by the time at which such soluble factors are 
added. Thus, Lyb-2 cell surface molecules evidently do not function as receptors for 
these differentiative signals. 
Reduction of PFC generation by Lyb-2 antibody is antigen dependent in the sense 
that reduction of the PFC response to one antigen (SRBC) does not affect subsequent 
generation  of PFC  to  a  second  antigen  (horse  erythrocytes)  from  the  same  cell 
population. These findings accord with the view that the Lyb-2 molecule participates 1316  Lyb-2 IN EARLY  B CELL  ACTIVATION 
in a  B cell differentiative phase, probably proliferative, which begins with binding of 
antigen and precedes the phase in which B cells become fully receptive to signals from 
T  and other ceils. 
We thank Dr. Peter Ralph for providing P388D.1  cell line, and Dr. Steven Gillis for purified 
TCGF. 
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